TRIADES: Safety and Efficacy Comparison Between CHF5993 100/6 12.5µg pMDI to Seretide Evohaler 125/25µg pMDI in Adolescent Subjects With Asthma (clinicaltrials.gov) - Oct 6, 2026 - P3 | N=700 | Not yet recruiting | Sponsor: Chiesi Farmaceutici S.p.A.
New P3 trial • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases
|